MRK241129C150000
- 0.00
- 0.000.00%
Merck & Co Newsroom
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Amgen, Boeing Share Losses Lead Dow's 200-Point Fall
Merck & Co. (MRK) Fell As It Faced Some Demand Headwinds In China
Daily short sale tracking: Nu Holdings's short volume increased by 25 million, with a short sale ratio of 31%
Dr. Reddy's Laboratories Launches Anti-Parasitic Drug Ivermectin
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $150
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
Today's Analyst Rating | UnitedHealth Price Target Raised to $655 by RBC Capital, Citi Upgrades Chevron to Buy
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123
Merck's "first-in-class" therapy Winrevair (sotatercept) achieved Phase 3 clinical primary endpoints.
Winrevair is a "first-in-class" type IIA activin receptor (ActRIIA) fusion protein.
BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $136
Nike, Sherwin-Williams Co. Share Gains Lead Dow's Nearly 250-Point Jump
Why Is Merck Stock Trading Higher On Monday?
Express News | Merck Shares up 2% After Therapy for Rare Lung Condition Showed Reduced Risk of Death in Study